December 13, 2011
Kissei Pharmaceutical Co., Ltd announced on December 12 that effective April 1, 2012, the company would transfer marketing rights for Cabaser (cabergoline) Tab. 0.25 mg and 1.0 mg, a treatment for Parkinson’s disease, to its manufacturer Pfizer Japan Inc. Cabaser...read more